D. E. Shaw & Co., Inc. - KARYOPHARM THERAPEUTICS INC ownership

KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 129 filers reported holding KARYOPHARM THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.44 and the average weighting 0.1%.

Quarter-by-quarter ownership
D. E. Shaw & Co., Inc. ownership history of KARYOPHARM THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$834,625
-22.0%
622,855
+4.2%
0.00%0.0%
Q2 2023$1,069,989
-50.0%
597,759
+8.8%
0.00%
-50.0%
Q1 2023$2,137,971
+104.2%
549,607
+78.5%
0.00%
+100.0%
Q4 2022$1,047,061
+33.4%
307,959
+114.1%
0.00%0.0%
Q3 2022$785,000
+197.3%
143,806
+145.8%
0.00%
Q2 2022$264,000
+5.2%
58,500
+71.5%
0.00%
Q1 2022$251,000
-77.8%
34,113
-80.6%
0.00%
-100.0%
Q4 2021$1,132,000
+625.6%
176,051
+1084.3%
0.00%
Q1 2021$156,000
-99.3%
14,865
-98.9%
0.00%
-100.0%
Q4 2020$21,396,000
-38.6%
1,382,133
-42.1%
0.02%
-47.2%
Q3 2020$34,857,000
-38.1%
2,387,470
-19.7%
0.04%
-46.3%
Q2 2020$56,347,000
+22.0%
2,975,015
+23.8%
0.07%
-6.9%
Q1 2020$46,177,000
+1.8%
2,403,780
+1.6%
0.07%
+38.5%
Q4 2019$45,346,000
+241.3%
2,365,511
+71.3%
0.05%
+225.0%
Q3 2019$13,285,000
+175.4%
1,381,027
+71.5%
0.02%
+166.7%
Q2 2019$4,824,000
+85.1%
805,462
+80.4%
0.01%
+100.0%
Q1 2019$2,606,000
+63.9%
446,375
+163.1%
0.00%
+50.0%
Q4 2018$1,590,000
-58.2%
169,668
-24.0%
0.00%
-60.0%
Q3 2018$3,802,000
+30.5%
223,263
+30.2%
0.01%
+25.0%
Q2 2018$2,914,000
+23.7%
171,512
-2.3%
0.00%
+33.3%
Q1 2018$2,356,000
+237.1%
175,541
+141.2%
0.00%
+200.0%
Q4 2017$699,000
+5.1%
72,771
+20.2%
0.00%0.0%
Q3 2017$665,000
-1.6%
60,549
-18.9%
0.00%0.0%
Q2 2017$676,000
-63.9%
74,673
-48.8%
0.00%
-66.7%
Q1 2017$1,872,000
+383.7%
145,765
+253.2%
0.00%
+200.0%
Q4 2016$387,000
+40.7%
41,270
+46.2%
0.00%
Q3 2016$275,000
-56.5%
28,219
-40.8%
0.00%
-100.0%
Q4 2015$632,000
+23.2%
47,700
-2.1%
0.00%0.0%
Q3 2015$513,00048,7000.00%
Other shareholders
KARYOPHARM THERAPEUTICS INC shareholders Q1 2023
NameSharesValueWeighting ↓
AIGH Capital Management LLC 1,773,474$2,376,4561.12%
AlphaCentric Advisors LLC 1,125,000$1,507,5000.86%
Tejara Capital Ltd 1,077,388$1,443,7000.82%
Palo Alto Investors LP 5,675,876$7,605,6740.72%
Birchview Capital, LP 571,832$766,2550.65%
Altium Capital Management LP 740,000$991,6000.52%
Avidity Partners Management LP 8,298,570$11,120,0840.45%
Worth Venture Partners, LLC 445,981$597,6150.36%
SILVERARC CAPITAL MANAGEMENT, LLC 561,955$753,0200.23%
DAFNA Capital Management LLC 192,678$258,1890.08%
View complete list of KARYOPHARM THERAPEUTICS INC shareholders